For other countries, any question or an interest in distributing OncoDEEP in your country please contact us at email@example.com
OncoDNA and Charles University Hospital, Prague, Czech Republic, announced today the launch of an ambitious research project on cancer of unknown primary site (CUP) in which Prof. Petruzelka, the principal investigator of the study, will use OncoDNA’s tumor profiling solution to decipher the complexity of the tumor and to identify the potential origin of the tumor. The study also aims at evaluating the different treatment strategies proposed by OncoDNA.
“We are very excited by this new initiative with the highly-esteemed Charles University Hospital. Precision medicine is revolutionizing the way cancer is diagnosed and treated and CUPs still account for 3 to 5% of all malignancies. Studying this disease is therefore particularly relevant and will reinforce treatment choice accuracy, striving for better outcomes for patients. It is a first important milestone to leverage knowledge on that cancer type and grant Czech doctors access to fast, comprehensive and relevant clinical information.” says Fiona Demol, International Business Development Manager at OncoDNA.
The study is done in coordination with OncoDNA’s distributor in Czech Republic, PentaGen, represented by Mr. Jiri Cizek.
“We are very proud to be part of this exciting project. This diagnostics tool can extend lives of many patients suffering from cancer. We hope it will become routine testing for more complicated cases that don’t fit in standard guidelines diagnostics.”, says Jiri Cizek, managing director at PentaGen.
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.